New SEER registry "big data" demonstrates the Oncotype DX® test accurately predicts clinical breast cancer outcomes, bringing the total number of patients in prospective outcome studies to 50,000

… DX® breast cancer test studies at the 38th CTRC-AACR San Antonio Breast Cancer Symposium … recurrence and breast cancer survival, in patients with early-stage invasive breast cancer. Data include … estrogen receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low …